Drug Trial Radar · NCT04229004
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
502
Actual
Start
Jan 31, 2020
Primary completion
Feb 5, 2025
Study completion Feb 5, 2025
Sponsor
- Lead sponsor
- Pancreatic Cancer Action NetworkAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. Primary Objectives * To compare each investigational arm versus standard of care (SOC) for superiority in overall survival in first and/or second line metastatic ductal adenocarcinoma (metastatic pancreatic cancer) participants and determine which, if any, participants benefit from each investigational arm. Secondary Objectives * To determine short and long-term safety signals of each investigational arm in metastatic pancreatic cancer participants vs. SOC. * To determine progression-free survival (PFS) for each investigational arm vs. SOC. * To determine rates of overall response, CR, and PR; duration of overall response, CR or PR (whichever occurs first). * To determine rates of clinical benefit; duration of clinical benefit.
Conditions
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Adenocarcinoma
Interventions
Gemcitabine combined with nab-paclitaxelDrug
Arm is closed to recruitment. Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines.
Dose -mFOLFIRINOXDrug
Arm is closed to recruitment. The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines.
Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxelDrug
Arm is closed to recruitment. Pamrevlumab 35mg/kg IV - Cycle 1 (Day 1, 8, 15 of the 28 day cycle) and Cycle 2 and Onward (Day 1 and 15) Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 for every 28 day cycle Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 for every 28 day cycle
Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabineDrug
Arm is closed to recruitment. Canakinumab 250mg SC- Day 1 of every 28 day cycle Spartalizumab 400 mg IV - Day 1 of every 28 day cycle Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 of every 28 day cycle Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 of every 28 day cycle
Drug: Dose -SM-88Drug
Arm is closed to recruitment. 460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: 0 weeks
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Diego (UCSD) - Moores Cancer Center
La Jolla, California
Cedars-Sinai Medical Center
Los Angeles, California
University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, California
University of Florida College of Medicine
Gainesville, Florida
Sylvester Comprehensive Cancer Center
Miami, Florida
The University of Chicago Medical Center
Chicago, Illinois
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan - Rogel Cancer Center
Ann Arbor, Michigan
Mayo Clinic Cancer Center (MCCC)
Rochester, Minnesota
Siteman Cancer Center - Washington University Medical Campus
St Louis, Missouri
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico
New York University Langone Medical Center - Perlmutter Cancer Center
New York, New York
Evelyn H. Lauder Breast Center - Memorial Sloan Kettering Cancer Center
New York, New York
Weill Cornell Physicians - Solid Tumor/Gastrointestinal Oncology
New York, New York
University of Cincinnati Cancer Institute
Cincinnati, Ohio
University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania
The University of Texas Southwestern Medical Center
Dallas, Texas
Baylor College of Medicine
Houston, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Commonwealth University School of Medicine
Richmond, Virginia
Virginia Mason Hospital & Seattle Medical Center
Seattle, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.